K-V Pharmaceutical Co - FORM 10-K - EX-23.1 - CONSENT OF BDO USA LLP - December 23, 2010

Attached files

file filename
10-K - FORM 10-K - K-V Pharmaceutical Cod10k.htm
EX-4.7 - PLEDGE AND SECURITY AGREEMENT - K-V Pharmaceutical Codex47.htm
EX-4.8 - PROMISSORY NOTE - K-V Pharmaceutical Codex48.htm
EX-4.9 - PROMISSORY NOTE - K-V Pharmaceutical Codex49.htm
EX-4.6 - CREDIT AND GUARANTY AGREEMENT - K-V Pharmaceutical Codex46.htm
EX-4.12 - REGISTRATION RIGHTS AGREEMENT - K-V Pharmaceutical Codex412.htm
EX-4.10 - STOCK PURCHASE WARRANT CERTIFICATE NO. W-1 - K-V Pharmaceutical Codex410.htm
EX-4.11 - STOCK PURCHASE WARRANT CERTIFICATE NO. W-2 - K-V Pharmaceutical Codex411.htm
EX-21 - LIST OF SUBSIDIARIES - K-V Pharmaceutical Codex21.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 - K-V Pharmaceutical Codex321.htm
EX-23.2 - CONSENT OF KPMG LLP - K-V Pharmaceutical Codex232.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - K-V Pharmaceutical Codex311.htm
EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 - K-V Pharmaceutical Codex322.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - K-V Pharmaceutical Codex312.htm
EX-10.31 - EMPLOYMENT AGREEMENT BETWEEN COMPANY AND THOMAS S. MCHUGH - K-V Pharmaceutical Codex1031.htm
EX-10.4 - K-V PHARMACEUTICAL COMPANY FIFTH RESTATED PROFIT SHARING PLAN & TRUST AGREEMENT - K-V Pharmaceutical Codex104.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

K-V Pharmaceutical Company

Bridgeton, MO

We hereby consent to the incorporation by reference in the Registration Statements (Nos. 33-44927, 333-00199, 333-48252 and 333-85516) on Form S-8 and the Registration Statements (Nos. 333-87402 and 333-106294) on Form S-3 of K-V Pharmaceutical Company (the Company) of our reports dated December 23, 2010 relating to the consolidated financial statements, financial statement schedule, and the effectiveness of K-V Pharmaceutical Company’s internal control over financial reporting included in this Annual Report on Form 10-K.

Our report on the effectiveness of internal control over financial reporting expresses an adverse opinion on the effectiveness of the Company’s internal control over financial reporting as of March 31, 2010.

Our report on the consolidated financial statements and financial statement schedule contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

/s/ BDO USA, LLP

Chicago, Illinois

December 23, 2010

K-V Pharmaceutical Co Reports

Also read